Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$796.20M+166.66%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Chirag K. Patel
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 8,700
- Beta
- 1.24
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.48
Financials
Revenue
$796.20M+166.7%Net Income
$57.66M+7.0%EBITDA
$193.78M+90.0%Free Cash Flow
$-64.85M-1355.2%EPS (diluted)
$0.18-37.9%Shares Outstanding (diluted)
328.10M+73.6%Operating Expenses
$189.83MCash & Debt
$127.64MReturn of Capital
$0.00Revenue by Segment (annual)
$528.51MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.02B | $72.06M | $0.23 |
| 2024 | $2.79B | $-116.89M | $-0.38 |
| 2023 | $2.39B | $-83.99M | $-0.48 |
| 2022 | $2.21B | $-129.99M | $-0.86 |
| 2021 | $2.09B | $10.62M | $0.07 |
| 2020 | $1.99B | $91.06M | $0.61 |
| 2019 | $1.63B | $-361.92M | $-4.57 |
| 2018 | $1.66B | $-169.73M | $-1.33 |
| 2017 | $1.03B | $167.65M | $1.46 |
| 2016 | $1.02B | $207.38M | $1.10 |
| 2015 | $866.28M | $169.45M | $0.90 |
| 2014 | $785.62M | $176.93M | $0.94 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AMRX's reported EPS growth of -12.0% a year over 11 years.
- EPS in 5 years
- $0.12
- Implied price
- $6.67
- Return from $20.24
- -19.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $3.32 — -83.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 39 | 47 | 55 | 63 | 71 |
|---|---|---|---|---|---|
| -22.0% | -33.7% | -31.2% | -29.0% | -27.0% | -25.3% |
| -17.0% | -29.5% | -26.8% | -24.5% | -22.4% | -20.5% |
| -12.0% | -25.2% | -22.4% | -19.9% | -17.7% | -15.7% |
| -7.0% | -21.0% | -18.0% | -15.3% | -13.0% | -10.9% |
| -2.0% | -16.7% | -13.6% | -10.8% | -8.3% | -6.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-28.57%Social Signal Score
Mentions (10)
- News (RSS)zerohedge·14d ago·Neutral
…as 25% after the healthcare software company cut its revenue guidance for FY27 amid disruption caused by a cyber security incident. Ipsen drops as much as 7.8% after Amneal Pharmaceuticals received FDA approval for its generic version of somatuline. Asian stocks advanced as an extended rally in semiconductor shares and a decline in oil prices supported investor sentiment. The MSCI Asia Pacific Index rose more than 1%, heading for a fourth straight session of gains. Samsung Electronics, TSMC and …
View source ↗ - Newsglobenewswire.com·17d ago·Positive
Amneal Announces FDA Approval and Launch of Lanreotide Injection - Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
View source ↗ - Newszacks.com·19d ago·Positive
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains? Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - News (RSS)yahoo·31d ago·Neutral
Amneal Pharmaceuticals (AMRX) Bets Big On Biosimilars While Wall Street Retreats
View source ↗ - Newszacks.com·40d ago·Positive
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low COCO, DAR, CNC, EXC and AMRX offer a defensive appeal as consumer confidence hits a 7-month low amid inflation and labor market concerns.
View source ↗ - Newszacks.com·47d ago·Neutral
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
View source ↗ - Newszacks.com·49d ago·Neutral
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns Five stocks, including CareDx and Caterpillar, cleared an efficiency screen based on key ratios exceeding industry averages.
View source ↗ - Newszacks.com·54d ago·Positive
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist? Amneal enters the second half of 2026 with higher guidance and a broader pipeline, but Rytary erosion and execution risks raise the stakes.
View source ↗ - Newszacks.com·54d ago·Positive
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now? Amneal 44.8% rally faces a test as earnings, launches and pipeline progress contend with Rytary erosion and a higher historical valuation.
View source ↗ - Newszacks.com·56d ago·Positive
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why Amneal (AMRX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
View source ↗
Earnings
Thu, Oct 29(in 3 weeks)
Consensus estimate $0.23 per share
Typical surprise +34.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.30 vs $0.22beat
- Thu, May 7$0.27 vs $0.17beat
- Fri, Feb 27$0.21 vs $0.18beat
- Thu, Oct 30$0.17 vs $0.13beat
- Tue, Aug 5$0.25 vs $0.18beat
- Fri, May 2$0.21 vs $0.15beat
Estimates and results for AMRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AMRX officers and directors.
- Bought
- —
- Sold
- $7.7m
0 trades
5 trades
- Kiely Johnsold
- Shah Nikitasold
- Daly Jason B.sold
- Daly Jason B.sold
- Autor Deborah M.sold
95 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA39 · disclosed Jun 18, 2019 (20d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jun 15, 2019 (22d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.